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ABSTRACT
Introduction: Multiple sclerosis (MS) is more
common in women and can occur during
childbearing years; thus, information on
outcomes following exposure to MS therapy
during pregnancy is important. No formal
studies of daclizumab have been conducted in
pregnant women. Here, we report available
nonclinical and clinical data on pregnancy
outcomes from the daclizumab clinical study
program.
Methods: Reproductive and developmental
toxicity studies were conducted in cynomolgus
monkeys. Reports of pregnancies that occurred
during the daclizumab clinical study program
through March 9, 2015 were collated and
summarized. In the event of pregnancy,
daclizumab was discontinued and safety
monitoring continued.
Results: Studies incynomolgusmonkeys showed
no daclizumab-related effects on maternal well-
being, embryo–fetal development, indirect
fertility end points, and pre- and postnatal
development and growth. Across the clinical
study program, 38 pregnancies were reported in
36 daclizumab-exposed women (on treatmentB6
months from last dose); 20 resulted in live births
and four (11%) in spontaneous abortions or
miscarriages. One congenital heart defect
(complex transposition of great vessels) occurred
in one live birth (considered unrelated to
daclizumab); daclizumab had been discontinued
and intramuscular interferon beta-1a and
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lisinopril were used at conception. Eight women
had an elective termination, two had an ectopic
pregnancy, and two were lost to follow-up; two
pregnancy outcomes are pending. Six additional
pregnancies occurred in five women[6 months
after their last daclizumab dose; in one additional
pregnancy, exposure was unknown.
Conclusion: Spontaneous abortion rate in
daclizumab-exposed women was consistent
with early pregnancy loss in the general
population (12%–26%). Data on pregnancies
exposed to daclizumab do not suggest an
increased risk of adverse fetal or maternal
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INTRODUCTION
The diagnosis of multiple sclerosis (MS) occurs
more frequently in women than men, with a
peak incidence during childbearing age, making
it important to understand the effects of
disease-modifying therapy (DMT) exposure on
pregnancy [1]. In clinical practice, many
European physicians prescribe DMTs up to the
time of conception to avoid the risk of disease
reactivation during withdrawal, with the advice
to cease therapy once pregnancy is confirmed
[1]. In the USA, it is more common to
recommend this clinical pathway only for
patients with highly active disease [2]. Thus,
data on exposure risks during pregnancy,
delivery, and postpartum are usually reported
from retrospective post-marketing follow-up or




mechanism of action compared with other DMTs.
Daclizumab binds to the high-affinity interleukin
2 (IL-2) receptor, resulting in attenuation of
proinflammatory activated T cell responses, and
substantial expansion and stimulation of
immune regulatory CD56bright natural killer (NK)
cells, which penetrate the blood–brain barrier
where it has been postulated that they lyse
activated T cells, leaving resting T cells intact
[3, 4]. Together, these immunomodulatory effects
are believed to reduce central nervous system
pathology in MS, decreasing relapses and
disability progression. Interestingly, elevated
circulating CD56bright NK cells also are associated
with decreased MS relapse rate in pregnancy
during the third trimester [5]. Also noteworthy is
that while uterine CD56bright NK cells are known
tobe involved insuccessful fetal implantation and
placental maturation, the phenotype differs from
the peripheral cells [6].
The nonclinical toxicology program was
designed to support the chronic subcutaneous
(SC) administration of daclizumab in relapsing
forms of MS. Daclizumab binds to cynomolgus
monkey CD25 and dose-dependently blocks
IL-2-dependent proliferation of effector T cells,
but does not bind to the analogous rat or
murine protein (AbbVie Biotherapeutics Inc.,
data on file). Human and cynomolgus monkey
CD25 share 92% sequence identity and
daclizumab binds with similar affinity to
recombinant human and cynomolgus monkey
1 Daclizumab high-yield process, approved as
ZinbrytaTM, has a different form and structure than an
earlier form of daclizumab (Zenapax).
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CD25 proteins (AbbVie Biotherapeutics Inc.,
data on file). Cynomolgus monkeys also have
been used to investigate the effects of CD25-
blocking antibodies in other models of disease,
including collagen-induced arthritis and
autoimmune uveitis [7, 8]. These in vitro and
in vivo data underpinned the use of the
cynomolgus monkey as a pharmacologically
relevant species for toxicology studies where
daclizumab was evaluated for its potential
effects on male and female fertility, embryo–
fetal development, and pre- and postnatal
development and growth.
The efficacy and safety findings for
daclizumab in patients with relapsing MS have
been reported from a large placebo-controlled
monotherapy registrational study [SELECT
(Clinicaltrials.gov identifier: NCT00390221)], as
well as the subsequent extension studies
[SELECTION (NCT00870740), SELECTED
(NCT01051349)], and from a large active-
controlled [intramuscular (IM) interferon
beta-1a] monotherapy phase III study [DECIDE
(NCT01064401)] [9–13]. Comparative clinical
data from patients with relapsing MS in
DECIDE showed that daclizumab 150 mg SC
every 4 weeks was superior to interferon beta-1a
30 mcg/week IM across a number of clinical,
magnetic resonance imaging, patient-reported,
and functional (e.g., cognitive) outcomes in the
overall study population, as well as in various
patient subgroups, and with a tolerability profile
largely reflective of its mechanism of action [11].
In general, the majority of adverse events seen
with daclizumab were mild or moderate in
intensity. Hepatic events, skin reactions, and
infections were observed at a higher incidence
with daclizumab than IM interferon beta-1a in
DECIDE [11]; however, rates did not appear to
increase over time [14]. Long-term data from the
SELECT Trilogy of studies showed that
daclizumab 150 mg efficacy continued over a
3-year period, with no evidence of accumulated
toxicity [9, 10, 12]. Formal studies of daclizumab
in pregnancy have not been conducted.
This report describes pregnancy outcomes in
patients with unintentional pregnancies that
occurred in the daclizumab clinical study
program as well as the nonclinical study results.
METHODS
Nonclinical
All the nonclinical studies, except the pre- and
postnatal study, utilized daclizumab SC, which
was formulated as follows: 100 mg/mL
daclizumab in vehicle (40 mM succinate buffer,
100 mM sodium chloride, and 0.03% Tween 80,
pH 6.0). For the pre- and postnatal study,
daclizumab was formulated in the same buffer,
but at 150 mg/mL. Control animals received the
vehicle. All studies were conducted in
compliance with Good Laboratory Practice
regulations using material representative of, or
identical to, the lots of drug substance used in the
production of the clinical drug. The reproductive
and developmental toxicity studies included
toxicokinetic assessments. Fetal exposure was
determined in an embryo–fetal study by analysis
of umbilical cord fluid levels at cesarean delivery,
and the pre- and postnatal study included
measurements of daclizumab in maternal and
offspring serum, and maternal milk. The
presence of antidrug antibodies (ADAs) and
neutralizing antibodies (NAbs) was assessed in
all studies.
Male Fertility Study
Groups of eight (0 and 200 mg/kg) and five
(10 and 50 mg/kg) sexually mature male
cynomolgus monkeys, 5.0–10.5 years of age,
received daclizumab once every 2 weeks for
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*60 days (to cover a complete spermatogenesis
cycle). One week following the final dose (fifth
dose, day 64), five animals per group were
necropsied; three animals in the control and
200-mg/kg groups remained on study for a
12-week postdose recovery period to assess the
reversibility of any potential daclizumab-related
effects. Male reproductive capacity was assessed
indirectly via sperm analysis (counts, motility,
and morphology) and serum testosterone levels,
which were evaluated twice pre study, twice
during dosing, and at the end of the recovery
period. A full histopathology evaluation that
included male reproductive tract tissues was
conducted.
Female Fertility Study
Groups of eight (0 and 200 mg/kg) or five (10
and 50 mg/kg) sexually mature female monkeys
received daclizumab once every 2 weeks for five
doses. Dosing was synchronized with each
animal’s menstrual cycle. Animals were dosed
over approximately two menstrual cycles,
followed by an 8-week postdosing recovery
period. Five animals per group were
euthanized on days 92–94 (35–37 days post
dosing). Three animals from the control and
the 200-mg/kg groups were continued on study
and euthanized on days 120–123, following a
*60-day postdose recovery period to assess the
reversibility of any potential daclizumab-related
effects. Female reproductive capacity was
assessed indirectly by changes in menstrual
cycle and ovarian function (assessed by
estradiol and progesterone levels during the
follicular and luteal phases of the menstrual
cycle). Full necropsy and histological evaluation
was performed at the end of the study,
including reproductive tract tissues and
adrenal and pituitary glands.
Embryo–Fetal Developmental Study
Groups of 12 (50 mg/kg), 13 (0 and 10 mg/kg),
and 15 (200 mg/kg) pregnant monkeys received
daclizumab (0, 10, 50, or 200 mg/kg) during the
period of organogenesis [i.e., B2 days of
confirmed pregnancy; gestation day (GD)
20–22] and weekly thereafter through GD50
for five doses. All adult females underwent
cesarean delivery on GD100 ± 2. Fetal
evaluations were conducted and consisted of
external and visceral examinations (including
fetal body weight, dimensions, and extensive
cardiac evaluations), skeletal examinations
(Alizarin Red-stained specimens), and organ
weights.
Pre- and Postnatal Developmental Study
Pregnant cynomolgus monkeys (20/group)
received daclizumab once weekly at 0 or 50 mg/
kg from GD50 until parturition (*GD160 ± 10).
For 6 months postpartum/postnatal (lactation
period), adult females and infants were
evaluated for changes in clinical signs, body
weight, hematology, lymphocyte phenotyping
evaluation [fluorescence-activated cell sorting
(FACS) analysis], toxicokinetics, ADAs, and/or
serum immunoglobulin analyses. Infants were
evaluated for developmental parameters,
including neurobehavioral and external
assessments, morphometric measurements, and
functional assessment of immune system [T cell-
dependent antibody response (TDAR) challenge].
Infants were euthanized on birth day 180 ± 1
(weaning) and external and visceral examinations
were conducted, including macroscopic and
microscopic tissue examinations.
All institutional and national guidelines for
the care and use of laboratory animals were
followed.
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Clinical
Pregnancy outcomes from adults with relapsing
MS who received at least one dose of
daclizumab in the phase II SELECT study [10],
phase III DECIDE study [11], and ongoing phase
III immunogenicity OBSERVE study, or their
respective extension studies [for SELECT:
SELECTION [9], SELECTED [12, 13]; for
DECIDE: EXTEND (NCT01797965)] were
included in this analysis.
All study designs were approved by
institutional review boards and conducted in
accordance with the International Conference
on Harmonisation Good Clinical Practice
guidelines and the Declaration of Helsinki and
its amendments. Informed consent was
obtained from all individual participants
included in the studies.
During the controlled studies, clinics visits
occurred every 4 weeks for daclizumab
administration and safety and tolerability
assessments; during the extension studies,
visits were every 4–12 weeks. Patients who
discontinued treatment were encouraged to
remain in the studies and complete follow-up
assessments as scheduled, with C6 months of
safety follow-up.
Females who were considering becoming
pregnant or who were currently pregnant or
breastfeeding were excluded from daclizumab
clinical studies. Male and female patients of
childbearing potential were required to practice
effective contraception and to continue
contraception for 4 months after their last
dose of study treatment. If a woman became
pregnant during any study, immediate
discontinuation of study treatment was
required. Investigators were required to report
pregnancies and the subsequent outcome.
Patients were considered to be exposed to
daclizumab from the time of the first dose of
daclizumab until 180 days (6 months) after
their last dose of daclizumab.
RESULTS
Nonclinical
A summary of reproductive and developmental
toxicity studies conducted with daclizumab in
cynomolgus monkeys is shown in Table 1.
Male Fertility Study
There were no daclizumab effects on mortality,
clinical signs, food consumption, sperm counts,
motility or morphology, serum chemistry or
hematology parameters, serum testosterone, or
organ weights, or any treatment-related
histologic findings in the reproductive tract in
male animals.
Exposure was confirmed in all treated
animals. No ADAs or NAbs to daclizumab were
detected. The no-observed-adverse-effect level
(NOAEL) was the highest dose evaluated
(200 mg/kg).
Female Fertility Study
There were no daclizumab-related effects on
mortality, clinical condition, food
consumption, body weight, clinical chemistry,
hematology parameters, estrogen and
progesterone levels, or fertility parameters
including histopathology. No treatment-
related changes in menstrual cycle or ovarian
function and no histopathologic changes in the
reproductive tract or adrenal and pituitary
glands were observed.
Exposure was confirmed in all treated
animals. Three animals tested positive for
daclizumab ADAs (10-mg/kg group, n = 2;
50-mg/kg group, n = 1). A strong NAb
response in one animal in the 10-mg/kg group
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was associated with a significant decrease in
serum daclizumab concentration on, and after,
day 57; the other ADA-positive animal showed
exposure levels similar to all other animals in
the group. In the 50-mg/kg group, NAb testing
was not performed due to weak transient ADA
response and high drug levels. The NOAEL was
the highest dose evaluated (200 mg/kg).
Embryo–Fetal Developmental Study
There were no daclizumab-related effects on any
of the pregnant animals. Food consumption,
body weight, body weight gain, and
hematology and serum chemistry parameters
were in normal ranges and comparable with
control animals.
Of the 53 cynomolgus fetuses, there were a
total of six losses across all groups, including
controls, with a slightly higher incidence in the
200-mg/kg group. However, the fetal loss was
not deemed related to daclizumab, as the
combined loss from the pilot (Biogen and
AbbVie Biotherapeutics Inc., data on file) and
Good Laboratory Practice studies was within the
range of spontaneous fetal loss for the test
facility, no developmental fetal effects were
observed, and a correlation was observed
between low maternal body weight and fetal
loss, with an uneven distribution of animals
with lower maternal body weights distributed to
receive 200 mg/kg (Biogen and AbbVie
Biotherapeutics Inc., data on file).
Table 1 Reproductive and developmental toxicity studies conducted with daclizumab in cynomolgus monkeys






Male fertility and early
embryonic development






Female fertility and early
embryonic development








Pre- and postnatal development GD50—parturition GD160 ± 10 0 50 55
50
GD gestation day, NOAEL (reproductive and developmental toxicity) no-observed-adverse-effect level
a Based on human exposure (area under curve for days 0–28) in OBSERVE, a pharmacokinetic study of daclizumab in
patients with multiple sclerosis [31]
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All other 47 cynomolgus fetuses (22 males, 25
females) showed normal growth and development
in utero. There were no daclizumab-related fetal
abnormalities (malformations and/or variations).
Maternal exposure was confirmed in all
animals. Average cord blood daclizumab
concentrations on GD100 ± 2 were 1.27, 9.23,
and 32.97 mcg/mL at dose levels of 10, 50, and
200 mg/kg, respectively, indicating placental
transfer. The maternal/fetal daclizumab ratio
at cesarean delivery was 0.5, 0.6, and 0.4 for the
10-, 50-, and 200-mg/kg groups, respectively.
Four animals dosed with 10 mg/kg daclizumab
had NAbs, coincident with pronounced drug
loss in one animal; the other three NAb-positive
animals showed no significant decrease in
exposure. These findings did not impact the
overall study conclusions. Maternal and
developmental NOAEL was the highest dose
evaluated (200 mg/kg).
Pre- and Postnatal Developmental Study
Weekly administration of 50 mg/kg daclizumab to
pregnant cynomolgus monkeys during gestation
was well tolerated; there were no daclizumab-
related changes in clinical signs, food
consumption, body weight, clinical pathology
(hematology), or serum immunoglobulins during
gestation through 6 months postpartum in female
cynomolgus monkeys. Effects on gestational
duration or pregnancy/postpartum outcomes
(i.e., combined fetal and infant losses) were
considered unrelated to maternal administration
of daclizumab.
Combined fetal and infant losses were
comparable between the controls (30%) and
daclizumab-treated (40%) animals and were
within the historical range for the testing
facility (10%–43%). There were three fetal
losses in the control group and one in the
daclizumab group, all occurring in the third
trimester.
A total of 17 control and 19 daclizumab-
exposed cynomolgus infants were delivered by
natural birth. There were ten infant losses
B29 days postnatally (control group, n = 3;
daclizumab group, n = 7). In four cases
(control group, n = 1; daclizumab group,
n = 3), the cause of death was clearly related to
lack of maternal care. In five cases (control
group, n = 2; daclizumab group, n = 3), the
infants were either delivered prematurely or
preterm, had injuries at delivery, or had survival
issues due to the mother’s poor health. One
infant was euthanized due to a fractured femur.
There were no daclizumab-related changes in
the fetuses/infants in any of the parameters
measured including clinical signs, body weight,
morphometric measurements, external
assessments, neurobehavioral evaluations,
clinical pathology (hematology), lymphocyte
phenotyping evaluation (FACS), serum
immunoglobulins, or TDAR.
No treatment-related effects were observed
in the available placenta or umbilical cord, or in
body weights, morphometric measurements,
external or gross/visceral evaluations, or
histopathology of the brain of aborted or
stillborn cynomolgus fetuses (control group,
n = 3; daclizumab group, n = 1), infants that
were euthanized or died before the scheduled
necropsy (control group, n = 3; daclizumab
group, n = 7), or in the remaining infants that
survived to scheduled necropsy on birth day
180 ± 1.
The mean ratio between daclizumab serum
concentrations in the cynomolgus infant and
corresponding mother 14 days after birth was
approximately one. Daclizumab was detected in
both the milk and serum of 9/19 animals 2
weeks after parturition; concentrations in milk
were B0.122% of that found in the serum of the
same animal.
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ADA samples were not analyzed, as decreased
exposure indicating ADAs was not detected. As
there were no daclizumab-related maternal or
developmental effects through 6 months
postpartum, NOAEL was determined to be
50 mg/kg.
Clinical Pregnancy Outcomes
A total of 2236 patients had received at least one
dose of daclizumab across the clinical study
program and, as of November 14, 2014, there
were 5213.6 patient-years of exposure. As of
March 9, 2015, 45 pregnancies in 40 patients
were reported with daclizumab; pregnancy
outcomes are shown in Table 2. There were 38
pregnancies in 36 women that occurred during
daclizumab exposure (on treatment or
B6 months from the last dose) and six
pregnancies in five women that occurred off
daclizumab treatment ([6 months after the last
dose).
In total, four women became pregnant more
than once: two were during daclizumab
exposure and then again[6 months after their
final dose of daclizumab and were counted in
both groups.
Among the 38 daclizumab-exposed
pregnancies, there were 20 live births, four
spontaneous abortions or miscarriages (11%),
eight elective terminations, and two ectopic
pregnancies. In patients with live births, the
mean number of doses before pregnancy was
13.3 (range 1–44), and in patients with
spontaneous abortions the mean number of
doses before pregnancy was 9.83 (range 2–21).
Two pregnancies were lost to follow-up and the
outcome for two is pending. A congenital
abnormality occurred in one live birth in
daclizumab-exposed pregnancies (see ‘‘Live
Births’’). There were three live births, two
spontaneous abortions, and one elective
termination in women who were off
daclizumab treatment at conception.
Live Births
Among live births from daclizumab-exposed
pregnancies (i.e., during treatment or
B6 months after last dose, n = 20), 18 were full
term (C36 weeks’ gestation), one woman gave
birth to twins via elective cesarean delivery at
32 weeks because of the twin pregnancy, and
gestational age at birth was unknown in one
woman. Maternal ages at conception ranged
from 22 to 38 years.
One congenital abnormality [heart defect:
complex transposition of great vessels (TGV)]
was observed in one live birth; the infant was
born to a woman who had received six doses of
daclizumab, but discontinued treatment
\4 months before conception and had been
receiving IM interferon beta-1a for 1 month at
the start of the pregnancy. She also had been
receiving lisinopril. Surgery was performed on
the infant to correct the complex TGV. The
investigator considered this congenital defect
unrelated to daclizumab.
Among live births from pregnancies that
occurred off daclizumab treatment (i.e.,
[6 months after last dose; n = 3), two were
full term (each delivered at 38 weeks). One was
delivered prematurely due to maternal history
of pre-eclampsia; the infant was healthy.
Maternal ages at conception ranged from 32 to
34 years.
Spontaneous Abortions
There were six spontaneous abortions in the
daclizumab clinical study program: four
occurred in pregnancies exposed to
daclizumab. At conception, the women’s ages
ranged from 26 to 33 years. Gestational ages at
the time of their final dose ranged from *2 to 4
weeks, and gestational ages at the time of
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spontaneous abortion ranged from 5 to 9 weeks.
Two of the four women had predisposing risk
factors (prior miscarriages and tobacco use) for
miscarriage [15]. In women who had been off
daclizumab treatment for [6 months at
conception, there were two spontaneous
abortions. Gestational ages at the time of
spontaneous abortion were *4 and *10
weeks; one of these women had had a prior
pregnancy during treatment with daclizumab
with an outcome of live birth.
Elective Terminations
Of the elective terminations reported in the
program, eight occurred in women exposed to
daclizumab at conception and one in a woman
who had been off daclizumab for [6 months.
One patient underwent an elective termination
because of a high risk of perinatal complications
and the procedure was performed without
problem. No fetal defects were reported.
Ectopic Pregnancies
Ectopic pregnancies occurred in two women (31
and 32 years of age when they became
pregnant) during daclizumab exposure. In one
patient, the gestational age at the time of the
last daclizumab dose was 10 weeks. In the other
patient, the ectopic pregnancy began 3 months
after the last dose. The gestational ages at the
Table 2 Pregnancy outcomes in the daclizumab clinical study program
Pregnancies by
outcomea
Became pregnant while receiving
daclizumab or £6 months after
the ﬁnal dose
Stopped daclizumab
treatment >6 months before
becoming pregnant
Daclizumab dose status

















Ectopic pregnancy 2 0 0
Lost to follow-up 2 0 0
Outcome pending 2 0 1
a Based on pregnancy reports from the daclizumab drug development program as of March 9, 2015
b Four women became pregnant more than once; two of these women became pregnant while receiving daclizumab or
B6 months of receiving the ﬁnal dose and then again[6 months after their ﬁnal dose of daclizumab and are therefore
counted in both columns
c Of the 36 women who became pregnant while receiving daclizumab or B6 months of receiving the ﬁnal dose, 34 had one
pregnancy (total pregnancies, n = 34) and two had two pregnancies in this category (total pregnancies, n = 4)
d In the ﬁve women who became pregnant[6 months after their ﬁnal dose of daclizumab, four had one pregnancy each
(total pregnancies, n = 4) and one had multiple (n = 2) pregnancies in this category
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time the pregnancies were terminated were *8
and *10 weeks. One of these women had a
history of miscarriage and had previously had a
spontaneous abortion (see ‘‘Spontaneous
Abortions’’) during the study at *2 months
before the ectopic pregnancy; she conceived
again at a later point in the study,[6 months
after the last dose, and gave birth to a healthy
infant. Formal medical details were not
available for the second ectopic pregnancy,
which was reported by the patient.
DISCUSSION
The reproductive and developmental toxicity
for daclizumab has been thoroughly evaluated
for effects on fertility, embryo–fetal
development, and pre- and postnatal
development and growth. In nonclinical
studies in cynomolgus monkeys, biweekly
(once every other week) daclizumab had no
effects on surrogate male or female fertility end
points at doses up to 200 mg/kg (highest dose
tested; exposure in females and males up to
85-fold and 100-fold higher than the clinical
dose, respectively). Once-weekly daclizumab at
doses up to 200 mg/kg in pregnant female
cynomolgus monkeys between GD20 and 50
(period of organogenesis) had no discernible
maternal or embryo–fetal effects. The 200-mg/
kg daclizumab dose corresponds to 140-fold
exposure at the efficacious 150-mg clinical dose.
In the pre- and postnatal study, once-weekly
administration of 50 mg/kg daclizumab from
GD50 until parturition in pregnant cynomolgus
monkeys was well tolerated. There were no
daclizumab-related maternal or developmental
effects through 6 months postpartum. The
frequency and nature of fetal and infant losses
that occurred were within the range of normal
variation for developmental and reproductive
toxicology studies at the testing facility and
within expected outcomes for live birth studies
of this type in cynomolgus monkeys [16]. Several
infant losses were secondary to maternal neglect,
which is a background finding in primigravid
cynomolgus monkeys [17]. The 50-mg/kg
daclizumab dose provided a 55-fold safety
margin over the clinical dose of 150 mg.
Across the daclizumab clinical study
program, 45 pregnancies have been reported,
38 of which occurred during daclizumab
exposure. Among pregnancies exposed to
daclizumab with known outcomes, 20/38 were
live births, 4/38 spontaneous abortions, 8/38
elective terminations, and 2/38 ectopic
pregnancies. The spontaneous abortions
occurred early in pregnancy (B10 weeks’
gestation) and the incidence in women
exposed to daclizumab (11%) was consistent
with the early pregnancy loss rate (12%–26%) in
the general population [15]. Two women who
conceived while receiving daclizumab were lost
to follow-up; outcomes are pending for two
pregnancies that occurred in women exposed to
daclizumab and one pregnancy for which the
timing of the last daclizumab dose is unknown.
Daclizumab exposure did not appear to be
associated with a higher risk of preterm births
[5% (1/20) of daclizumab-exposed pregnancies],
which was comparable with the rate reported in
the general population (5%–10%) [18]. No
patterns of specific birth defects were
observed, with one congenital abnormality of
complex TGV reported in the fetus of a woman
who stopped daclizumab treatment\4 months
before becoming pregnant and was receiving IM
interferon beta-1a for 1 month, concomitant
with lisinopril, at conception; this event was
not considered by the investigator to be
treatment related.
The estimated half-life of daclizumab is
21–25 days and is characterized by slow
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clearance [19]; therefore, there is potential for
fetal exposure when pregnancy begins B6
months of the last dose. In terms of
pharmacodynamics, that daclizumab may
affect uterine CD56bright NK cells also should
be considered; however, the expansion of the
phenotypically different peripheral CD56bright
cells was reversible following 24 weeks of
treatment discontinuation [9]. Thus, exposure
risk should be considered in women receiving
daclizumab and who wish to conceive.
Pregnancy outcomes have been reported from
post-marketing surveillance, prospective
observational studies, and analyses of clinical
trial databases for SC interferon beta-1a [20], IM
interferon beta-1a [21], interferon beta-1b [22],
glatiramer acetate [23], natalizumab [24, 25],
fingolimod [26], teriflunomide [27], delayed-
release dimethyl fumarate (DMF; also known as
gastro-resistant DMF) [28], alemtuzumab [29],
and the chemotherapeutic agent mitoxantrone
[30]. Overall, data regarding the effects of
interferon beta and glatiramer acetate on
fertility, pregnancy, and lactation are relatively
reassuring [1, 30]. Animal studies have indicated
that natalizumab administration may result in
reduced fertility, with no human studies
published to date [1, 30]. The most recent data
from the natalizumab pregnancy registry do not
suggest any effect of exposure on pregnancy
outcomes [25]; nevertheless, except for severely
active cases, natalizumab should not be used
before conception [30]. While fingolimod does
not appear to negatively impact fertility, cases of
abnormal fetal development, coupled with a
teratogenic effect in animals, mean that
avoiding its use in pregnancy is strongly
recommended [1, 30]. Teriflunomide does not
affect the overall fertility in animal studies,
despite reducing sperm counts in rats [30].
Results from a retrospective analysis global
pharmacovigilance database do not indicate a
teratogenic signal nor other adverse pregnancy
outcomes [27]. Nevertheless, based on
nonclinical leflunomide data, teriflunomide has
a black box warning for teratogenicity and is
therefore contraindicated in pregnant women or
women of childbearing potential who are not
using reliable contraception [30]. Some
regulatory authorities also have recommended
that men wishing to father a child should
discontinue teriflunomide and undergo the
accelerated elimination procedure due to its
presence in human semen at low levels [27].
Delayed-release DMF did not appear to impair
fertility or exert teratogenic effects in animals;
data from clinical trials and post-marketing
databases do not suggest an increased risk of
fetal abnormalities or adverse pregnancy
outcomes with gestational exposure [28].
Fertility and pregnancy outcome data are
limited for alemtuzumab; animal studies
indicate possible reproductive toxicity, while
exposure during the clinical trial program does
not suggest a teratogenic risk [29, 30].
Mitoxantrone has shown embryotoxicity in
animal and human studies; therefore,
pregnancy should be excluded before each
infusion [30]. Overall, treatment benefits for
the mother (or father) must be balanced against
potential risks to the fetus when deciding how to
manage planned pregnancies.
CONCLUSION
In summary, animal studies showed no effects
of daclizumab on maternal well-being, embryo–
fetal development, fertility, and pre- and
postnatal development and growth. The
numbers of pregnancies in the daclizumab
clinical study program are small and therefore
do not allow definitive conclusions. In addition,
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patients enrolled in clinical studies may not be
wholly representative of the overall population
of individuals with MS. However, data on
pregnancies in women exposed to daclizumab
during the clinical study program do not
suggest an increased risk of adverse pregnancy
outcomes with regard to the fetus or mother.
Data from any further pregnancies occurring
during the ongoing extension studies and in
post-marketing experience will continue to be
collected.
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